DEA Disconnect Leads to Buprenorphine Bottlenecks.
Journal
Journal of addiction medicine
ISSN: 1935-3227
Titre abrégé: J Addict Med
Pays: Netherlands
ID NLM: 101306759
Informations de publication
Date de publication:
Historique:
pubmed:
13
11
2020
medline:
24
8
2021
entrez:
12
11
2020
Statut:
ppublish
Résumé
To describe a buprenorphine dispensing bottleneck resulting from a pharmacist-perceived Drug Enforcement Administration "cap" on the amount of buprenorphine that can be ordered or stocked. Expert review and preliminary fieldwork. We find no such cap exists, though medication distributors struggle to accurately understand and interpret regulatory guidelines, with implications for medication availability.In states where opioid overdose rates remain higher and efforts to increase the number of eligible health care providers prescribing medications to treat opioid use disorder are underway, patients prescribed buprenorphine products report difficult filling prescriptions and pharmacists perceive limits on how much medication they can order and stock. We recommend Drug Enforcement Administration policy clarifications or changes to facilitate distributor interpretation; pharmacist workflow; and patient access to medication. We also advise continuing education with pharmacists and buprenorphine prescribers. These steps would facilitate greater access to lifesaving treatment for opioid use disorder.
Identifiants
pubmed: 33181577
pii: 01271255-202108000-00003
doi: 10.1097/ADM.0000000000000762
doi:
Substances chimiques
Analgesics, Opioid
0
Buprenorphine
40D3SCR4GZ
Types de publication
Editorial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
272-275Informations de copyright
Copyright © 2020 American Society of Addiction Medicine.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
ACOG. 2018. “Opioid Use and Opioid Use Disorder in Pregnancy - Committee Opinion.” ACOG Committee on Obstetric Practice. ACOG. Available at: https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Obstetric-Practice/Opioid-Use-and-Opioid-Use-Disorder-in-Pregnancy . Accessed November 28, 2019.
American Pharmacists Association. 2020. Increasing Access to and Advocacy for Medications for Opioid Use Disorder (MOUD). Actions of the 2020 House of Delegates – Special Session. Available at: https://www.pharmacist.com/sites/default/files/audience/2020_Report_of_the_APhA_Virtual_House_of_Delegates-FINAL_2.pdf . Accessed August 10, 2020.
Carroll J, Green T, Noonan R. Evidence-Based Strategies for Preventing Opioid Overdose: What's Working in the United States, 2018. Centers for Disease Control; 2018. Available at: https://www.cdc.gov/drugoverdose/pdf/pubs/2018-evidence-based-strategies.pdf . Accessed December 2, 2019.
Coe MA, Lofwall MR, Walsh SR. Buprenorphine pharmacology review: update on transmucosal and long-acting formulations. J Addict Med 2019; 13 (2):93–103.
Cooper HLF, Cloud DH, Freeman PR, et al. Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: a case study of the rural risk environment in Appalachian Kentucky. Int J Drug Policy 2020; 102701DOI 10.1016/j.drugpo.2020.102701.
doi: 10.1016/j.drugpo.2020.102701
Cooper HLF, Cloud DH, Young AM, et al. When prescribing isn’t enough;1; — pharmacy-level barriers to buprenorphine access. N Engl J Med 2020; 383 (8):703–705.
Croke LM. Management of chronic pain and opioid misuse: a position paper from the AAFP. Am Fam Physician 2017; 95 (7):458–459.
Davis CS, Carr DH. Legal and policy changes urgently needed to increase access to opioid agonist therapy in the United States. Int J Drug Policy 2019; 73:42–48.
Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol 2012; 10 (6):209–219.
DEA. Exempt Prescription Products. 2020. Available at: https://www.deadiversion.usdoj.gov/schedules/exempt/exempt_rx_list.pdf#search=exempt%20prescriptin . Accessed May 1, 2020.
Fiscella K, Wakeman SE, Beletsky L. Buprenorphine deregulation and mainstreaming treatment for opioid use disorder: X the X Waiver. JAMA Psychiatry 2019; 76 (3):229–230.
Haelle T. Pharmacist Stigma a Barrier to Rural Buprenorphine Access. MEdge Psychiatry 2019; July. Available at: https://profreg.medscape.com/px/sso/oauthlogin?oauth=1&client_id=29210617-47A2-49CB-A6C8-38A252ED3F14&response_type=code&redirect_uri=https%3A//www.mdedge.com/services/medauth/authenticated&state=https%253A%252F%252Fwww.mdedge.com%252Fpsychiatry%252Farticle%252F205251%252Faddiction-medicine%252Fpharmacist-stigma-barrier-rural-buprenorphine-access&status=5eec9b2ff34b8 . Accessed November 22, 2019.
Hawk KF, Vaca FE, D’Onofrio G. Reducing fatal opioid overdose: prevention, treatment and harm reduction strategies. Yale J Biol Med 2015; 88 (3):235–245.
Ostrach B, Foley K, Harless JC. Evaluation report: increasing workforce capacity for medication-assisted treatment (MAT). Evaluation Report, UNC Health Sciences at MAHEC: prepared for and submitted to North Carolina Dept. of Health and Human Services; 2019.
Raisch DW, Fudala PJ, Saxon AJ, et al. Pharmacists’ and Technicians’ perceptions and attitudes toward dispensing buprenorphine/naloxone to patients with opioid dependence. J Am Pharm Assoc 2005; 45 (1):23–32.
Society of Hospital Medicine. SHM Position on Buprenorphine Deregulation. 2019. Available at: https://www.hospitalmedicine.org/globalassets/policy-and-advocacy/advocacy-pdf/shm-buprenorphine-deregulation-2019---statement.pdf . Accessed August 10, 2020.
TxMOUD. 2020. “GetWaiveredTX.” Texas Medication for Opioid Disorder (TxMOUD). 2020. Available at: https://txmoud.org/ . Accessed May 1, 2020.
Waters RC. In support of buprenorphine deregulation. Fam Pract Manag 2019; 26 (4):6–8.